KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Goodwill & Intangibles (2018 - 2025)

Historic Goodwill & Intangibles for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $24.9 million.

  • Vir Biotechnology's Goodwill & Intangibles fell 3131.56% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.9 million, marking a year-over-year decrease of 3131.56%. This contributed to the annual value of $25.1 million for FY2024, which is 3656.78% down from last year.
  • Vir Biotechnology's Goodwill & Intangibles amounted to $24.9 million in Q3 2025, which was down 3131.56% from $24.9 million recorded in Q2 2025.
  • In the past 5 years, Vir Biotechnology's Goodwill & Intangibles registered a high of $50.6 million during Q1 2021, and its lowest value of $24.9 million during Q3 2025.
  • Its 5-year average for Goodwill & Intangibles is $41.4 million, with a median of $42.5 million in 2023.
  • In the last 5 years, Vir Biotechnology's Goodwill & Intangibles tumbled by 102.79% in 2021 and then tumbled by 3656.78% in 2024.
  • Quarter analysis of 5 years shows Vir Biotechnology's Goodwill & Intangibles stood at $50.2 million in 2021, then fell by 1.06% to $49.7 million in 2022, then fell by 20.51% to $39.5 million in 2023, then crashed by 36.57% to $25.1 million in 2024, then dropped by 0.78% to $24.9 million in 2025.
  • Its last three reported values are $24.9 million in Q3 2025, $24.9 million for Q2 2025, and $25.0 million during Q1 2025.